Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0
Sign in

SRR1442885

GTEX

31d7d6df-c829-5380-8503-a9c69f26fbcb

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
subtype
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.327
  • MYOGENESIS+0.266
  • BILE_ACID_METABOLISM+0.131
  • SPERMATOGENESIS+0.093
  • HEDGEHOG_SIGNALING+0.066
  • ESTROGEN_RESPONSE_LATE-0.010
  • HEME_METABOLISM-0.036
  • UV_RESPONSE_DN-0.060
  • ESTROGEN_RESPONSE_EARLY-0.075
  • FATTY_ACID_METABOLISM-0.075

Top 10 suppressed

  • IL6_JAK_STAT3_SIGNALING-0.552
  • MYC_TARGETS_V1-0.546
  • MTORC1_SIGNALING-0.516
  • TNFA_SIGNALING_VIA_NFKB-0.483
  • E2F_TARGETS-0.473
  • G2M_CHECKPOINT-0.468
  • UNFOLDED_PROTEIN_RESPONSE-0.451
  • INFLAMMATORY_RESPONSE-0.441
  • INTERFERON_GAMMA_RESPONSE-0.441
  • INTERFERON_ALPHA_RESPONSE-0.421

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR821581
brain-umap@2
GTEX0.950
2SRR1414833
brain-umap@2
GTEX0.945
3SRR1432343
brain-umap@2
GTEX0.945
4SRR1466850
brain-umap@2
GTEX0.944
5SRR1070986
brain-umap@2
GTEX0.938
6SRR1477634
brain-umap@2
GTEX0.938
7SRR1325986
brain-umap@2
GTEX0.938
8SRR1404640
brain-umap@2
GTEX0.937
9SRR1359388
brain-umap@2
GTEX0.936
10SRR1406561
brain-umap@2
GTEX0.934

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 5 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.327Remibrutinib— uncovered
MYOGENESIS0.266Inavolisib— uncovered
BILE_ACID_METABOLISM0.131Inavolisib— uncovered
SPERMATOGENESIS0.093Inavolisib— uncovered
HEDGEHOG_SIGNALING0.066Inavolisib— uncovered